🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Forget BiTEs, what about tri-specific T-cell engagers? Conceptually tempting in many ways & promising in this early study. Seems more scalable than some cellular therapy options - so def one to watch #EULAR2025 LB0007 Dr. John Cush (&slide from Helga Lechner-Radner’s highlights)

What a pleasure and honour to be invited as a speaker at #EULAR2025 in Barcelona 🇪🇸 for the session “JAK it out! New perspectives on JAK inhibitors” by EULAR with David Liew. I presented on JAK inhibitors and malignancy: is it really a big deal? 👇 Summary thread 🧵

Many thanks David Liew and Prof Parick Kiely #haemochromatosis #ironoverload

Still more to catch up on #EULAR2025: More good news for anti-FcRn therapy - this time in myositis Perhaps an obvious target indication, but need more steroid-sparing options in myositis (&thanks again for Helga Lechner-Radner's highlights slide) #EULAR2025 OP0002 Dr. John Cush

Dual JAK/ROCK inhibition: anti-ROCK meant to improve HDL function & also endothelial i.e. improve vascular health An enticing idea Do these changes in lipids vs other studies convince you something's here? #EULAR2025 OP0193 Dr. John Cush also The Lancet Rheumatology thelancet.com/journals/lanrh…

Steroids, Not JAKi, Are the Real Infection Risk Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain. buff.ly/8wgjPp5

Polymyalgia rheumatica: killing them softly Linked Comment by David Liew & Claire Owen bit.ly/4eiha6W

“Normal” CPK by race and gender. ⁦Rohit Aggarwal⁩ ⁦Florida Society of Rheumatology⁩

Does Abatacept Buy You Time Off RA? Dr. David Liew reports on abstract OP0325 presented at the 2025 EULAR meeting in Barcelona, Spain. buff.ly/E4pxW4o

JAK Inhibitors: The Latest from the JAK-pot Study Dr. David Liew reports on abstract POS0150 - Evolution of Janus Kinase Inhibitors (JAKi) Prescriptions Since 2015 In An International Collaboration of Rheumatoid Arthritis Registers (The 'JAK-pot' Study): Effect of Regulatory

What would it take for JAKs to ROCK the boat? JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. Once the

Current controversies in ANCA-associated vasculitis therapy: pulse steroids PEXIVAS reduced dose GC low-dose CYC+ritux PLEX ritux dosing (lovely table NatRevRheumatol from some great minds in AAV including Marta Casal Moura Andreas Kronbichler Benjamin Terrier Stephen McAdoo & many others)

Jekyll and Hyde: which RA-ILD is it? Dr. David Liew reports on abstract OP0329 presented at the EULAR 2025 meeting in Barcelona, Spain. buff.ly/vKkxQZb

JAK Inhibitors: The Latest from the JAK-pot Study Dr. David Liew reports on abstract POS0150 - Evolution of Janus Kinase Inhibitors (JAKi) Prescriptions Since 2015 In An International Collaboration of Rheumatoid Arthritis Registers (The 'JAK-pot' Study): Effect of Regulatory

Latest atlas article out Rheumatology & Rheumatology Advances in Practice Rheumatology Advances in Practice: Imaging of gout (an area with lots of nuance) very pretty images but also lots of great practical hints from Emma Rowbotham & Luqman Wali Well worth checking out & it's open access: academic.oup.com/rheumap/articl…

What can make flares of gout more likely? (and what can be done about it?) credit: NatRevRheumatol nature.com/articles/s4158…

Amazing that, after that magnitude of positive phase 2 result for secukinumab in GCA (TitAIN) as below ⬇️ that the phase 3 secukinumab in GCA (GCAptAIN) could fail its primary endpoint and multiple key secondaries. Stunning globenewswire.com/news-release/2…

Now that the subsequent phase 3 (GCAptAIN) has failed, worth full reflection. I won’t pretend I didn’t subsequently buy into the excitement about secukinumab and GCA in the lead-up to Thursday’s announcement, but I should have listened to earlier me (who had appropriate caution)